Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies - The Lancet Neurology
![PDF] Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5d15ee3d04b0d11f0a390f7be905dde1382712ba/3-Figure1-1.png "PDF] Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine | Semantic Scholar")
PDF] Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine | Semantic Scholar
A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs - ScienceDirect
A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs - Journal of Biological Chemistry
A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs - ScienceDirect
3,4-Diaminopyridine 54-96-6 wiki
3,4-Diaminopyridine | ≥99%(HPLC) | Selleck | Others
Amifampridine for the Management of Lambert-Eaton Myasthenic Syndrome: A New Take on an Old Drug - Connie H. Yoon, Jocelyn Owusu-Guha, Adam Smith, Pamela Buschur, 2020
Brain Sciences | Free Full-Text | Presynaptic Paraneoplastic Disorders of the Neuromuscular Junction: An Update | HTML
LEMS Facts | FIRDAPSE® (amifampridine)
Acetylator Status Impacts Amifampridine Phosphate (Firdapse™) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function - Clinical Therapeutics
3,4-Diaminopyridine | C5H7N3 - PubChem
Randomized, placebo-controlled trials with 3,4-diaminopyridine in... | Download Table
Amifampridine - Wikipedia
Neurology Today
Profile of aminopyridines for Lambert–Eaton myasthenic syndrome | ODRR
Structure-activity relationship studies of four novel 4-aminopyridine K+ channel blockers | Scientific Reports
Aminopyridines for the treatment of neurologic disorders. - Abstract - Europe PMC
Randomized, placebo-controlled trials with 3,4-diaminopyridine in... | Download Table
Lambert-Eaton Syndrome - Neurology - Medbullets Step 1
Frontiers | Autoregulation of Acetylcholine Release and Micro-Pharmacodynamic Mechanisms at Neuromuscular Junction: Selective Acetylcholinesterase Inhibitors for Therapy of Myasthenic Syndromes | Pharmacology
Frontiers | Pathomechanisms and Clinical Implications of Myasthenic Syndromes Exacerbated and Induced by Medical Treatments | Molecular Neuroscience
A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs - Journal of Biological Chemistry
3,4-Diaminopyridine | C5H7N3 - PubChem
A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs - ScienceDirect
